Last reviewed 2026-04-23 · How we verify

TORIPALIMAB INJECTION(JS001 )

Toripalimab is a PD-1 inhibitor that blocks the PD-1/PD-L1 interaction to enhance T-cell mediated anti-tumor immunity.

Toripalimab is a PD-1 inhibitor that blocks the PD-1/PD-L1 interaction to enhance T-cell mediated anti-tumor immunity. Used for Metastatic non-small cell lung cancer, PD-L1 positive, Metastatic nasopharyngeal carcinoma, Locally advanced or metastatic esophageal squamous cell carcinoma.

At a glance

Mechanism of action

By inhibiting the PD-1/PD-L1 interaction, toripalimab allows T-cells to recognize and attack cancer cells more effectively. This mechanism is thought to be responsible for its anti-tumor activity.

Approved indications

• Metastatic non-small cell lung cancer, PD-L1 positive
• Metastatic nasopharyngeal carcinoma
• Locally advanced or metastatic esophageal squamous cell carcinoma

Common side effects

• Fatigue
• Nausea
• Diarrhea
• Rash
• Pyrexia

Key clinical trials

• PDT For Induction Therapy For Head And Neck Cancer (PHASE2)
• Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors (PHASE1, PHASE2)
• JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer (PHASE1, PHASE2)
• DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer (PHASE2)
• A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer (PHASE2, PHASE3)
• The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer (PHASE3)
• Toripalimab or Placebo With Paclitaxel and Cisplatin in Esophageal Squamous Cell Carcinoma (PHASE3)
• A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.